Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fighting fire with fire: rekindling the bevacizumab debate.

Literature DB >> 22276827

Fighting fire with fire: rekindling the bevacizumab debate.

Alberto J Montero, Charles Vogel.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2012 PMID： 22276827 DOI： 10.1056/NEJMe1113368

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

14 in total

1. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

Authors: D Zhao; C Pan; J Sun; C Gilbert; K Drews-Elger; D J Azzam; M Picon-Ruiz; M Kim; W Ullmer; D El-Ashry; C J Creighton; J M Slingerland
Journal: Oncogene Date: 2014-08-25 Impact factor: 9.867

2. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

Authors: William Cruz-Muñoz; Teresa Di Desidero; Shan Man; Ping Xu; Maria Luz Jaramillo; Kae Hashimoto; Catherine Collins; Myriam Banville; Maureen D O'Connor-McCourt; Robert S Kerbel
Journal: Angiogenesis Date: 2014-02-26 Impact factor: 9.596

3. Scheduling of anticancer drugs: timing may be everything.

Authors: Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal: Cell Cycle Date: 2012-10-03 Impact factor: 4.534

4. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.

Authors: Alberto J Montero; Deukwoo Kwon; Aurea Flores; Krisztina Kovacs; Jonathan C Trent; Pasquale Benedetto; Caio Rocha-Lima; Jaime R Merchan
Journal: Clin Cancer Res Date: 2016-02-10 Impact factor: 12.531

10. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Authors: José R Rossari; Otto Metzger-Filho; Marianne Paesmans; Kamal S Saini; Alessandra Gennari; Evandro de Azambuja; Martine Piccart-Gebhart
Journal: J Oncol Date: 2012-09-12 Impact factor: 4.375

Fighting fire with fire: rekindling the bevacizumab debate.

1. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.

2. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.

3. Scheduling of anticancer drugs: timing may be everything.

4. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.

Review 5. Tivozanib: current status and future directions in the treatment of solid tumors.

Review 6. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

Review 7. After counterfeit Avastin®--what have we learned and what can be done?

Review 8. Relapsed triple-negative breast cancer: challenges and treatment strategies.

9. Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer.

10. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.